ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
复制标题

DOI：
10.1093/annonc/mdu385
复制
发表时间：
2014-10
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
通讯作者：
Winer E
Winer E
中科院分区：
其他
文献类型：
--
作者：
Cardoso F;Costa A;Norton L;Senkus E;Aapro M;André F;Barrios CH;Bergh J;Biganzoli L;Blackwell KL;Cardoso MJ;Cufer T;El Saghir N;Fallowfield L;Fenech D;Francis P;Gelmon K;Giordano SH;Gligorov J;Goldhirsch A;Harbeck N;Houssami N;Hudis C;Kaufman B;Krop I;Kyriakides S;Lin UN;Mayer M;Merjaver SD;Nordström EB;Pagani O;Partridge A;Penault-Llorca F;Piccart MJ;Rugo H;Sledge G;Thomssen C;Van't Veer L;Vorobiof D;Vrieling C;West N;Xu B;Winer E
来源链接：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176456/?report=classic

文献摘要

参考文献

被引文献

相似文献

""
FIRST ISOLATED LOCOREGIONAL RECURRENCE FOLLOWING MASTECTOMY FOR BREAST-CANCER - RESULTS OF A PHASE-III MULTICENTER STUDY COMPARING SYSTEMIC TREATMENT WITH OBSERVATION AFTER EXCISION AND RADIATION
DOI： 10.1200/jco.1994.12.10.2071
发表时间： 1994-10-01
期刊： JOURNAL OF CLINICAL ONCOLOGY
影响因子： 45.3
作者：
BORNER, M;BACCHI, M;BRUNNER, K
通讯作者： BRUNNER, K
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
DOI： 10.1200/jco.2011.39.0708
发表时间： 2012-08-01
期刊： JOURNAL OF CLINICAL ONCOLOGY
影响因子： 45.3
作者：
Bachelot, Thomas;Bourgier, Celine;Pujade-Lauraine, Eric
通讯作者： Pujade-Lauraine, Eric
Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.
DOI： 10.1016/j.breast.2013.07.050
发表时间： 2013-10
期刊： Breast (Edinburgh, Scotland)
影响因子： --
作者：
Cardoso F;Bese N;Distelhorst SR;Bevilacqua JL;Ginsburg O;Grunberg SM;Gralla RJ;Steyn A;Pagani O;Partridge AH;Knaul FM;Aapro MS;Andersen BL;Thompson B;Gralow JR;Anderson BO
通讯作者： Anderson BO
Breast cancer with synchronous metastases: Trends in survival during a 14-year period
DOI： 10.1200/jco.2004.08.095
发表时间： 2004-08-15
期刊： JOURNAL OF CLINICAL ONCOLOGY
影响因子： 45.3
作者：
Andre, F;Slimane, K;Spielmann, M
通讯作者： Spielmann, M
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
DOI： 10.1016/s1470-2045(13)70502-3
发表时间： 2013-12
期刊： The Lancet. Oncology
影响因子： --
作者：
Buzdar AU;Suman VJ;Meric-Bernstam F;Leitch AM;Ellis MJ;Boughey JC;Unzeitig G;Royce M;McCall LM;Ewer MS;Hunt KK;American College of Surgeons Oncology Group investigators
通讯作者： American College of Surgeons Oncology Group investigators